Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-DTK-COV19 in Severe COVID-19 Patients
NCT07709637Phase 1Active, not recruiting
- Sponsor
- LucasBio
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB-DTK-COV19 in coronavirus disease 2019 (COVID-19), sponsored by LucasBio. Primary endpoints: NCI-CTCAE v5.0 >= Grade 3 Rate at 24 weeks, Adverse Events at 24 weeks and 6 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
LB-DTK-COV19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07709637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709637.